<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82203">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01777048</url>
  </required_header>
  <id_info>
    <org_study_id>203/12</org_study_id>
    <nct_id>NCT01777048</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids Supplementation in ADHD</brief_title>
  <official_title>Augmenting the Effects of Methylphenidate: A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids Supplementation in Children With Attention Deficit Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitäre Psychiatrische Kliniken (UPK) Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching aim of the proposed study is to assess whether omega-3 fatty acids
      supplementation can augment the effects of methylphenidate in children with ADHD. The
      investigators hypothesized that omega-3 fatty acids supplementation will be associated with
      improved ADHD symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in ADHD Rating Scale-IV total score</measure>
    <time_frame>Baseline, Week 6, and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Child Behaviour Checklist total score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g of Omega-3 per day [400mg DHA &amp; 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 Fatty Acids Supplementation</intervention_name>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 Placebo</intervention_name>
    <description>Placebo capsules manufactured to mimic Omega-3 capsules</description>
    <arm_group_label>Omega-3 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants between ages 6 and 12 years who:

          1. have been clinically diagnosed with ADHD by a physician

          2. meet the criteria of ADHD-Inattention, ADHD-Hyperactivity-Impulsivity, or
             ADHD-Combined type as determined by the SNAP-IV (Swanson, 1992)

          3. are willing to participate in a randomized, double-blind, placebo-controlled trial,
             complete with written, informed parental consent,

          4. are on stable dosage of methylphenidate treatment before the start of the study

          5. are able to speak English or German

        Exclusion Criteria:

          1. Participants who are younger than 6 years old or older than 12 years old

          2. Those who have not been clinically diagnosed with ADHD by a physician

          3. Those who did not meet the criteria of ADHD-Inattention,
             ADHD-Hyperactivity-Impulsivity, or ADHD-Combined type as determined by the SNAP-IV
             (Swanson, 1992)

          4. Those without written parental consent

          5. Those with brain pathology such as serious head injury, epilepsy, and intellectual
             disability (IQ &lt; 70)

          6. Those with titrated dosage of methylphenidate before the start of the study

          7. Those on neurofeedback training, and/or psychosocial intervention addressing
             attention problems

          8. Those with known hypersensitivity to the IMP under investigation

          9. Those who are unable to read and understand the parent/participant information

         10. Those receiving medications other than methylphenidate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon Phaik Ooi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sibylle Meier</last_name>
    <email>sibylle.meier@stud.unibas.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitäre Psychiatrische Kliniken (UPK) Basel</name>
      <address>
        <city>Basel</city>
        <zip>4058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oliver Pick, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klaus Schmeck, Dr. med Dip.-Psych.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Gaab, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 15, 2013</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Yoon Phaik Ooi</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
